Navigation Links
Origin BioMed Awarded Red Herring Top 100 Global Company

Halifax-based consumer health products company recognized as a world technology leader

HALIFAX, Nova Scotia, Jan. 27 /PRNewswire/ -- Origin BioMed Inc., a privately-held Canadian consumer health products company, today announced that it has been awarded as one of the Red Herring Top 100 Global Companies.

Red Herring Top 100 Global Companies are chosen from winners and finalists of the previous competitions for North America, Europe and Asia Red Herring Top 100 Companies. Out of 1,800 successful and highly eligible companies, the Red Herring editorial team deployed a detailed process to drill-down the best companies first to 200 finalists, then to the top 100 winners of this global award. Evaluations were made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration.

The announcement of the winners was made at the Red Herring 100 Global taking place in San Diego from January 14-16, 2009. Present among the finalists were elite executives and venture capital leaders from around the world.

"We were so pleased to announce Origin BioMed Inc. as a Red Herring Top 100 Global Company," commented Red Herring publisher Alex Vieux. "Origin BioMed has proven to be a company excelling in their industry and its ripples have turned into waves. It was difficult for us to narrow down, but we are pleased to have included Origin BioMed in our list of promising companies. We look forward to the changes it makes to the non-prescription drug industry in the future." Origin was one of only 4 Canadian companies to receive the Award, with companies from 25 other countries also receiving the award.

"Since its inception, Origin's mission has been to leverage cutting edge technology to bring scientifically proven natural products to professional care givers and consumers. We strive to increase over-the-counter treatment options for nerve pain, and Red Herring's recognition demonstrates that our model has begun to position us as a global leader in our field," said Robert Cervelli, President and CEO, Origin BioMed. "It was a real honour to accept this award on behalf of the entire dynamic team at Origin," he added.

Origin BioMed's leading drug product, Neuragen(R), is the first non-prescription topical treatment for rapid relief of diabetic and post-shingles nerve pain. Neuragen(R) is available in all leading pharmacies in Canada and the United States.

About Origin BioMed Inc.

Origin BioMed, Inc. is a privately-held Canadian consumer health products company with business operations throughout the U.S. and Canada. Headquartered in Halifax, Nova Scotia, Origin BioMed Inc. manufactures health products with the highest quality active ingredients, at therapeutic levels, with evidence of scientific or clinical efficacy since 2001. Its leading drug product, Neuragen(R), helps relieve pain caused by diabetic nerve damage. For more information, please visit: or

    Robert Silverstein
    VP Operations

About Red Herring

Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available on the Internet at

    Anam Alpenia
    Red Herring, Inc.
    Phone: 650-428-2900

SOURCE Origin BioMed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
2. Covance Decides to Pursue Its Original Preclinical Strategy in China
3. Brewing better beer: Scientists determine the genomic origins of lager yeasts
4. San Diegos Original Biotech Company Celebrates 30th Anniversary With Reunion
5. Experts prove the geochemical origin of part of the CO2 emissions in semiarid climates
6. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
7. Three Expert Opinion Journals now Publishing Original Research
8. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
10. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
11. Bavarian Nordics Case Against Oxford BioMedica
Post Your Comments:
(Date:11/30/2015)...  Champions Oncology, Inc. (CSBR), engaged in the development ... development and use of oncology drugs, today announced that ... presenting at the LD MICRO Investor Conference on Wednesday, ... The conference, held at the Luxe Sunset Bel Air ... will feature 200 small/micro-cap companies and is expected to ...
(Date:11/30/2015)... Ill. , Nov. 30, 2015  AbbVie, is ... program that focuses on a daily routine for managing ... take their medication can affect the way the body ... follow to their a daily routine are important. The ... to help patients better manage their hypothyroidism by establishing ...
(Date:11/28/2015)... ... 2015 , ... • Jeon Jin Bio Corp, a Korean Biotech venture company, ... , Bird Free, an oil-based, gel formula made ... including visual, smell, taste and touch, enabling safe, effective avian control without toxic chemicals ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
Breaking Biology News(10 mins):